Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 233
- 试验地点
- 4
- 主要终点
- Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic
研究概览
简要总结
In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months.
The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ocular pathology requiring repeated IVT treatment of anti-angiogenic drugs (exudative AMD, diabetic macular edema or secondary to retinal venous occlusion ...)
- •Beginning of IVT treatment repeated before 10/01/2019 (6 months before the start of French confinement)
排除标准
- •Refusal to participate
结局指标
主要结局
Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic
时间窗: Baseline (Before confinement) and 6 months after resumption of follow-up
Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
次要结局
未报告次要终点